Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103116 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer
A Phase 2 study of Lung Cancer, sponsored by Edward Hirschowitz.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT00103116: Completed Phase 2 study of Lung Cancer, sponsored by Edward Hirschowitz.
NCT00103116 is a Phase 2 study of Lung Cancer that has completed, run by Edward Hirschowitz. The registered enrollment target is 32 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00103116, a Phase 2 study of Lung Cancer, has completed, sponsored by Edward Hirschowitz.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Vaccines made from a person's white blood cells and allogeneic tumor cells may make the body build an effective immune response to kill tumor cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with stage I, stage II, or stage III non-small cell lung cancer.
Conditions Studied
Interventions
- BIOLOGICAL autologous dendritic cell cancer vaccine
Study Locations (1)
Kentucky
- Markey Cancer Center at University of Kentucky Chandler Medical Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2004-10 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103116
The ClinicalTrials.gov registry entry for NCT00103116 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Edward Hirschowitz, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which autologous dendritic cell cancer vaccine is the first listed.
NCT00103116 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT00103116 about?
NCT00103116 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer". RATIONALE: Vaccines made from a person's white blood cells and allogeneic tumor cells may make the body build an effective immune response to kill tumor cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with stage I, stage II, or stage III non-small...
What is the current status of trial NCT00103116?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2004-10. Estimated completion is 2008-04.
What conditions does trial NCT00103116 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00103116?
The interventions under investigation include: autologous dendritic cell cancer vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00103116?
This trial is sponsored by Edward Hirschowitz, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00103116 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.